A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients

  • Shailesh Nagpure Department of Pharmacology, Jawaharlal Nehru Medical College, Sawangi, Wardha
  • Ranjana Kale Department of Pharmacology, Mahatma Gandhi Institute of Medical Sciences, Sewagram, Wardha
  • Swanand Pathak Department of Pharmacology, Jawaharlal Nehru Medical College, Sawangi, Wardha
  • Satyavan Patel Department of Pharmacology, Jawaharlal Nehru Medical College, Sawangi, Wardha
Keywords: Post-menopausal, osteoporosis, leprosy, Ibandronate Risedronate


Objectives: The aim of the current investigation was to compare relative efficacy, tolerability and adherence of once monthly regimen of oral Ibandronate and Risedronate in postmenopausal osteoporotic leprosy patients with its impact on severity of the disease and quality of life.

Method:This double blind, comparative study was conducted among 200 postmenopausal osteoporotic leprosy patients. The enrolled participants were screened for various diagnostic parameters. The participants were randomized in a 1:1 ratio to receive either oral Ibandronate (150 mg single tablet- once monthly) or oral Risedronate (150 mg single tablet- once monthly) for a period of one year.

Results: Present study showed that treatment with both Ibandronate and Risedronate increased hip BMD, and Z-test with repeated measurements was used to examine the significance of the longitudinal changes in the BMD. The difference in the efficacy of the two drugs in increasing hip BMD might be attributed to the greater efficacy of Ibandronate in reducing bone turnover than that of Risedronate.

Conclusion: Once monthly Ibandronate has a potential to decrease the severity of osteoporosis as compared to once monthly Risedronate. Also, the quality of life in terms of general health status, physical activity and pain, limitation in daily activity and the emotional status in postmenopausal osteoporotic leprosy patients is better with Ibandronate than that of Risedronate.


Download data is not yet available.


. Action Plan Osteoporosis: consensus statement of an expert group. Osteoporosis society of India (2003) New Delhi.

. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet, 2002;359: 2018-26.

. P. Moonot, N. Ashwood, D. Lockwood; Orthopedic complications of Leprosy. J Bone Joint Surg [Br], 2005;87-B:1328-1332.

. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004; 19:12411249.

. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo ClinProc, 2005; 80:379388. PubMed

. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:13441352.

. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med, 1995; 333:14371443.

. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res, 2005; 20:13151322.

. Bartl R, Goette S, Hadji P, Hammerschmidt T. Persistence and compliance with daily and weekly administered bisphophonates for osteoporosis treatment in Germany. OsteoporosInt, 2005;16 Suppl 3: S45.

. Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Does dosing regimen impact persistence with bisphosphonate theapy among postmenopausal osteoporotic women. J Bone Miner Res 2004; 19:S448

. Ettinger MP, Gallagher R, Amonkar M, Mahoney PM, Gilbride J. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum, 2004;50: S513

. Y.-S. Chung et al.: Ibandronate versus Risedronate in Asians. Calcif Tissue Int, 2009; 85:389397.

. Jun Iwamoto. Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis.Yonsei Med J, 2008;49(1):119-128.

. K Akan, H Cift, K Ozkan. Osteoporosis and clinical outcomes in itertrochantric hip fractures. J Inter Med Res, 2011;39:857-865.

. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res, 1994;9:1137-1141.

. Badia X, Diez P, Lahoz R. The ECOS-16 Questionnaire for the evaluation of health related quality of life in elderly with osteoporosis. Health Quality Life Outcomes, 2004; 2:41.

. Badia X, Dez-Prez A, Alvarez-Sanz C, Daz-Lpez B, Daz-Curiel M, Guilln F. Spanish GRECO Study Group, Measuring quality of life in women with vertebral fractures due to osteoporosis. A comparison of the OQLQ and QUALEFFO. Qual Life Res, 2001;10:307-317.

. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab, 1994;79:1693-700.

. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the longterm response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res, 1998;13:1431-8.

. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes

CJ, Wasnich RD, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab, 2000;85:3109-15.

. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab, 2007; 25:302309.

. Hubert H, Blosh D, Fries J, Risk Factors for Physical Disability in an Aging Cohorts: The NHANES Epidemiologic Follow Up Study. J GerontolNurs, 2004; 12 (2):61-73.

. Schoen C. The Impact of Osteoporosis on Quality-of-Life: The Ofely Cohort. Orthopedic Essentials: Research Update. OrthopNurs, 2003; 22(2):150 - 52.

. Taft L, Looker P, Cella D. Osteoporosis: a disease management opportunity. OrthopNurs, 2000;19(2):67-79.

How to Cite
Nagpure, S., Kale, R., Pathak, S., & Patel, S. (2017). A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients. International Journal of Biomedical and Advance Research, 8(11), 407-415. https://doi.org/10.7439/ijbar.v8i11.4474
Original Research Articles